Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancerTodd W. Miller, Carlos L. Arteaga|Breast Cancer Research|2011Cited by 463
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with PertuzumabOtto Metzger, Ian E. Krop, Giuseppe Viale et al.|Cancer Discovery|2021Cited by 241
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancerMichalina Janiszewska, Kornélia Polyák, Lin Liu et al.|Nature Genetics|2015Cited by 166
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated TumorKevin Kalinsky, Keith T. Flaherty, Fangxin Hong et al.|JAMA Oncology|2020Cited by 106
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.Otto Metzger, Ian E. Krop, Giuseppe Viale et al.|Journal of Clinical Oncology|2019Cited by 82